Medical AM Market Outlook 2026–2036: Market Size, Growth Drivers, Key Companies, Strategic Developments & Adoption Forecast for Patient-Specific Implants and Point-of-Care Printing — A Meticulous Next™ Foresight Brief

This Meticulous Next™ brief examines how medical additive manufacturing, meaning the 3D printing of implants, surgical guides, anatomical models and instruments from titanium, polymers and other biomaterials, shifts from a specialist service at central factories to patient-specific production at or near the point of care over the next ten years. The change runs from the scan of a patient to the implant in the operating room, and in 2026 the regulator showed that a hospital can hold the clearance.

The case begins with fit. A standard implant comes in a few sizes, and surgeons adjust it in theatre. A printed implant is designed from the scan of the patient, can include fixation features in the design and can use porous structures that bone grows into. Printing also uses material only where it is needed. In 2024 3D Systems said that additive manufacturing uses up to 85% less material than machining for its PEEK cranial implants. These are company claims, but they explain why cranial, facial, spinal and orthopaedic devices are early uses.

The first proof arrived in 2024. 3D Systems received FDA 510(k) clearance for its patient-specific VSP PEEK Cranial Implant solution in April 2024, the first FDA cleared additively manufactured PEEK implant for cranioplasty. The cleared workflow combines segmentation software, the EXT 220 MED printer and Evonik VESTAKEEP i4 3DF PEEK, and it is designed to run in a hospital. A cleared workflow that can sit inside a hospital is the technical basis for point-of-care production.

The second proof is regulatory. Walter Reed National Military Medical Center obtained 510(k) clearance in June 2026 for its Titanium Cranial Plate System, and 3D Systems announced it on 28 July 2026 as the first FDA clearance for an implant granted to a point-of-care institution. The submission was sponsored by the Defense Health Agency Office of Regulated Activities, and was cleared on the first attempt. Walter Reed can now supply the design and process to other approved military treatment facilities, and a hospital that holds a clearance changes who counts as a medical device manufacturer.

Commercial models are adjusting. Hospitals need quality systems, design software, printers and trained staff, and suppliers sell them as packages. Ricoh USA sold its point-of-care patient-specific device unit to a management buyer, which rebranded it Myrava, and a Madrid public hospital became a certified medical device manufacturer under EU rules. The more institutions that hold the right quality systems, the more printing moves from the supplier to the hospital.

The brief maps the technology, its indicative market size and forecast, the factors behind its growth, the developments of the last 24 months, the key players and the adoption trajectory to 2036.

It is a focused 107-page decision brief for medical device makers, hospitals, additive manufacturing suppliers, material makers, investors and regulators. It presents an indicative trajectory rather than a segmented market model. Its purpose is to identify which devices and settings adopt printing first, how clearances and quality systems sequence demand, and who captures value as printing moves toward the patient.

Medical additive manufacturing builds devices layer by layer from a digital model. Powder bed fusion of titanium makes implants with porous surfaces for bone growth. Material extrusion and other processes print PEEK and PEKK polymers, which are radiolucent and close to bone in stiffness. Vat photopolymerisation makes surgical guides and anatomical models. Each route needs validated settings and biocompatible materials.

The workflow matters as much as the printer. A patient scan is segmented, a surgeon and engineer design the implant, the part is printed, cleaned, inspected and sterilised, and records are kept. The Walter Reed Titanium Cranial Plate was designed with fixation bars built in, so surgeons do not add hardware during surgery. Every step sits inside a quality management system, and the clearance covers the whole process, not only the machine.

Point-of-care production changes the supply chain. A hospital with a cleared workflow can produce an implant in days rather than weeks, and can share its design with other approved facilities. Earlier point-of-care cases, such as a PEEK cranial implant at University Hospital Basel in 2023 and a facial implant reported in 2025, relied on the clearance or conformity of the supplier workflow. The Walter Reed clearance is different because the institution itself holds it.

Materials are broadening. Titanium remains the standard for load-bearing and cranial plates, and PEEK and PEKK are growing for cranial, facial and spinal uses. Researchers are testing bioprinted tissue, including vascularised bone, though these remain at the research stage and are outside the market definition. Material makers such as Evonik and Victrex supply medical grades that are qualified for printing.

The constraints are regulation, cost of quality systems and skills. The FDA discussion paper of 2021 on point-of-care manufacturing left the framework unsettled, so each institution works case by case. A hospital needs design engineers, validated processes and audit capacity. Reimbursement for patient-specific devices varies. The decade turns on whether regulators set a clear route for institutions and whether payers recognise the clinical value.

The medical am market, covering printed implants and instruments, anatomical models and surgical guides, point-of-care printing systems, medical grade materials, design software and related services, and excluding bioprinted living tissue, conventional implant machining and dental appliances sold as consumer products, is valued at USD 6–8 billion in 2026 and is projected to reach USD 20–28 billion by 2036, at a CAGR of 13%.

The 2026 base rests on printed orthopaedic and spinal implants from medtech companies, surgical guides and anatomical models, printers and materials sold to hospitals and device makers, and design and quality services. From that base, growth follows the spread of patient-specific devices and the move of production toward the hospital. As cleared workflows multiply, each institution adds printers, materials and software.

The forecast is sensitive to the regulatory path for point-of-care manufacturing, reimbursement and the cost of quality systems. Regionally, North America leads on cleared workflows and military and academic hospitals, Europe on conformity under the EU Medical Device Regulation and on hospital manufacturers, and Asia-Pacific on volume production and growing hospital adoption.

The base case assumes gradual regulatory clarity, growing numbers of cleared workflows and steady payer recognition, giving the inflection around 2030. An accelerated case adds clear regulatory guidance, wide design hub networks and broad reimbursement, bringing the inflection to 2028 and lifting the 2036 value to the top of the range. A delayed case assumes unsettled regulation and payer resistance, holding growth at the bottom of the range.

Growth drivers

• Clinical demand for patient-specific fit in cranial, facial, spinal and orthopaedic reconstruction.
• Regulatory milestones: FDA clearance of a PEEK workflow (April 2024) and of a point-of-care institution implant (June 2026).
• Faster delivery and design sharing across approved facilities.
• Material savings and design freedom, including porous structures and built-in fixation.

Enablers

• Cleared workflows that combine software, printer and material.
• Quality management systems and regulatory support from suppliers such as 3D Systems.
• Medical grade materials from Evonik, Victrex and titanium powder makers.
• Military and academic hospitals with design and engineering teams.

Restraints and barriers

• Unsettled regulatory framework for point-of-care manufacturing.
• Cost of quality systems, validation and audit capacity.
• Shortage of design engineers and trained staff in hospitals.
• Uneven reimbursement for patient-specific devices.

Five converging forces will determine how fast medical AM scales.

(1) Regulatory route for institutions. (2) Clinical evidence and reimbursement. (3) Cleared workflows and materials. (4) Hospital quality and design capacity. (5) Cost and speed against standard implants. The brief assesses each force for direction, speed and confidence.

The key players operating in medical additive manufacturing include 3D Systems Corporation, Stratasys Ltd., Materialise NV, Stryker Corporation, Zimmer Biomet Holdings, Inc., Johnson & Johnson, Medtronic plc, Smith & Nephew plc, Globus Medical, Inc., Enovis Corporation, restor3d, Inc., Evonik Industries AG, Victrex plc, Formlabs Inc., Carbon, Inc., EOS GmbH, Nikon SLM Solutions AG, Renishaw plc, Align Technology, Inc., Dentsply Sirona Inc., Straumann Holding AG, Orthofix Medical Inc., Ricoh Company, Ltd., Myrava, Insight Surgery, Axial3D, Oxford Performance Materials, Inc., Carpenter Technology Corporation, ATI Inc., Lima Corporate S.p.A., Walter Reed National Military Medical Center, the Defense Health Agency, University Hospital Basel, Mayo Clinic, Clalit Health Services, the US Food and Drug Administration, the European Commission, ASTM International, the International Organization for Standardization and the Fraunhofer-Gesellschaft.

The brief profiles representative players in each archetype and assesses which are positioned to lead as printing moves toward the point of care.

The competitive landscape is forming around six archetypes. Printing and workflow suppliers. Medtech implant makers. Materials suppliers. Software and service providers. Hospitals and military treatment facilities. Regulators and standard-setters. Competitive intensity is high in 2026 and is expected to rise as hospitals gain clearances and device makers defend their implant lines through 2032.

Where value migrates.

In 2026 value sits in printers, materials and medtech implant lines. By 2030 it moves to cleared workflows, quality systems and design software that let hospitals manufacture. By 2036 it settles in software and quality platforms, medical grade materials and device makers that partner with hospital networks. Standard sized implants lose standing in complex cases.

The signals converge on clearance and institutions. A PEEK workflow cleared in 2024, an institution implant cleared in 2026, a Madrid hospital certified and commercial point-of-care units changing hands. Clinical work is widening, from cranial implants to a PEKK chest cage. Each signal moves medical printing from a service bought from a factory toward a capability held by a hospital.

Research and patent activity reflects where the chain is weakest: accuracy of point-of-care printing, validation of processes, bioprinted tissue and evidence for outcomes. The brief therefore tracks four indicators: the number of cleared point-of-care workflows, the number of hospitals certified as manufacturers, the share of complex reconstructions using patient-specific devices and reimbursement decisions.

Regionally, North America leads on cleared workflows and military and academic hospitals, Europe on conformity under the EU rules and hospital manufacturers, and Asia-Pacific on volume production. Cranial and maxillofacial, spinal, orthopaedic and dental uses are the first demand pools.